doi: 10.1016/j.cmet.2022.10.001 5 Wewer AlbrechtsenNJPedersenJGalsgaardKDWinther-SorensenMSuppliMPJanahLet al
This article provides evidence-based information to help patients and healthcare professionals navigate this complex topic, emphasising the importance of open communication with prescribers about all substance use
Addressing these and other vital clinical questions will require additional investment in basic, translational, clinical and implementation research. They conclude: The management of hyperglycaemia in type 2 diabetes has become extraordinarily complex with the number of glucose-lowering medications now available
Consistency also helps reduce side effects
These GLP-1 drug lawsuits are being filed individually across multiple jurisdictions and are not currently part of the existing multidistrict litigation (MDL) focused on gastrointestinal injuries like gastroparesis
In April 2025, AstraZeneca Plc could receive European Medicines Agency (EMA) approval for ECC5004, its oral GLP-1RA, for the treatment of obesity, intensifying competition in the oral treatment segment